EU Regulators On Forecasting Demand For Medicines In A Pandemic
A Harmonized Approach Can Help Assess Future Needs
The coronavirus pandemic has taught us some lessons on estimating future drug manufacturing requirements, but any forecasts will need to take a whole range of variables into account.
You may also be interested in...
A project is about to begin to understand the factors that influence marketing decisions in the various EU member states.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
Regulatory bodies from Australia, Canada and the UK say a new pilot program will reduce the need for multiple inspections of the same site, while an MoU signed by Australia and Canada will cut the amount of documentary evidence required from drug sponsors seeking GMP clearances.